DYADIC INTERNATIONAL INC
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company based in Jupiter, Florida, that develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes. The company operates through its proprietary microbial expression platforms, primarily the C1 system… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What DYADIC INTERNATIONAL INC does
In the company’s own words
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company based in Jupiter, Florida, that develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes. The company operates through its proprietary microbial expression platforms, primarily the C1 system based on the Thermothelomyces heterothallica fungus and the Dapibus™ platform, which enable scalable and cost-effective production of recombinant proteins across multiple markets. The company's website is www.dyadic.com.
Dyadic's business model centers on commercializing recombinant proteins through direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing agreements that may include annual licensing fees, milestone payments, development funding, and revenue-sharing arrangements. The company targets three primary market segments: life sciences applications including cell culture media components and molecular biology reagents; food and nutrition markets featuring dairy proteins and functional ingredients; and bio-industrial applications encompassing biomass processing and industrial enzymes.
The company has undergone significant strategic evolution. Following its 2015 sale of industrial technology assets to DuPont's Danisco subsidiary, Dyadic retained important rights to sublicense the C1 platform for pharmaceutical applications while maintaining royalty participation on future commercialization. This transaction allowed the company to redirect focus toward advancing C1 for biopharmaceutical use while developing the Dapibus™ platform to address non-pharmaceutical markets with shorter regulatory timelines and faster commercialization paths.
Recent commercial achievements include the launch of AlbuFree™ DX recombinant human albumin through partner Proliant Health and Biologicals and recombinant DNase I through collaboration with Fermbox Bio. The company has also established development and commercialization agreements with partners including Inzymes ApS for dairy enzymes and The Protein Collective B.V. for recombinant dairy ingredients.
As of December 31, 2025, Dyadic employed five full-time employees and maintained a satellite office in the Netherlands alongside its primary U.S. operations. The company estimates its total addressable market across life sciences, food and nutrition, and bio-industrial segments at over twenty-five billion dollars, positioning itself as a next-generation platform provider in the global protein production landscape.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- JUPITER, FL
- Fiscal year end
- December
- CIK
- 1213809
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns DYADIC INTERNATIONAL INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · DYADIC INTERNATIONAL INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do DYADIC INTERNATIONAL INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of DYADIC INTERNATIONAL INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in DYADIC INTERNATIONAL INC's last four quarterly filings that the numbers alone won't show?”